Drug extends survival in lung cancer patients
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
Limited (HUTCHMED) (HCM) announced that the New Drug Application (NDA) for the combination of ORPATHYS(savolitinib) ...
Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...
Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback